Prognostic Parameters for Response to Enzalutamide After Docetaxel and Abiraterone Treatment in Metastatic Castration-Resistant Prostate Cancer Patients; a Possible Time Relation

Author(s):
Badrising, S.K.; Noort, V. van der; Eertwegh, A.J.M. van den; Hamberg, P.; Oort, I.M. van; Berg, H.P. van den; ; Aarts, M.J.B.; Coenen, J.L.L.M.; Gelderblom, H.; Jong, I.J. de; Kerver, E.D.; Vrijaldenhoven, S.; Voorthuizen, T. van; Warmerdam, F.; Haanen, J.B.; Bergman, A.M.; DUOS
Published
2016
Publication type
Article / Letter to editor
prostate cancerenzalutamideabirateronedocetaxelcross-resistanceAR plasticity
Date issued
2016-01-01
Language
English
Is part of
Prostate (2016), Vol. 76, no. 1, p. 32-40
hdl
1887/112901
doi
10.1002/pros.23094